Mitsubishi Tanabe Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MITSUBISHI TANABE, and what generic alternatives to MITSUBISHI TANABE drugs are available?
MITSUBISHI TANABE has two approved drugs.
There are five US patents protecting MITSUBISHI TANABE drugs.
There are twenty patent family members on MITSUBISHI TANABE drugs in fourteen countries.
Summary for Mitsubishi Tanabe
International Patents: | 20 |
US Patents: | 5 |
Tradenames: | 2 |
Ingredients: | 1 |
NDAs: | 2 |
Patent Litigation for Mitsubishi Tanabe: | See patent lawsuits for Mitsubishi Tanabe |
Drugs and US Patents for Mitsubishi Tanabe
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 10,987,341 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,957,660 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Mitsubishi Tanabe | RADICAVA ORS | edaravone | SUSPENSION;ORAL | 215446-001 | May 12, 2022 | RX | Yes | Yes | 11,478,450 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mitsubishi Tanabe
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-001 | May 5, 2017 | 6,933,310 | ⤷ Sign Up |
Mitsubishi Tanabe | RADICAVA | edaravone | SOLUTION;INTRAVENOUS | 209176-002 | Nov 15, 2018 | 6,933,310 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mitsubishi Tanabe Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3875085 | ⤷ Sign Up |
Japan | WO2020091036 | ⤷ Sign Up |
South Korea | 20210087490 | ⤷ Sign Up |
Brazil | 112021008197 | ⤷ Sign Up |
Japan | 7274502 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.